ZYVOXAM 100 MG / 5 ML
LINEZOLID : 100 MG / 5 ML · DIN 02243686 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is ZYVOXAM?
ZYVOXAM 100 MG / 5 ML contains LINEZOLID : 100 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02243686, held by PFIZER CANADA ULC, supplied as POWDER FOR SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 04-Aug-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ZYVOXAM used for?
ZYVOXAM (linezolid injection and powder for oral suspension) is indicated for: Treatment of adult patients with Vancomycin-Resistant Enterococcus faecium (VREF) Infections, Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (penicillin-susceptible strains only), Community-acquired pneumonia caused by Streptococcus pneumoniae (penicillin-susceptible strains only) including cases with concurrent bacteremia or Staphylococcus aureus (methicillin-susceptible and -resistant strains), Complicated skin and skin structure infections, including non-limb threatening diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is ZYVOXAM called?
The same molecule, LINEZOLID, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Linezolid Accord | Latin | Czechia, Norway, Sweden |
| Linezolid Krka | Latin | Czechia, Norway, Sweden |
| Zersa | Latin | Bahrain, Saudi Arabia |
| Linezolid Sandoz | Latin | Czechia, Norway, Sweden |
| Zenix | Latin | Bahrain, Saudi Arabia |
| Linezolid Fresenius Kabi | Latin | Norway |
| LINEZOLID OLIKLA | Latin | Czechia |
| Voxwin Tablets | Latin | South Africa |
| Zillion | Latin | Saudi Arabia |
| Zodinex | Latin | Bahrain, Saudi Arabia |
| ZYVOX | Latin | Bahrain |
| ZYVOXID | Latin | Czechia |
| Aklid | Latin | South Africa |
| ELTURIN IV | Latin | South Africa |
| KINZADO | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02243686 |
|---|---|
| Brand name | ZYVOXAM |
| Generic / active ingredient | LINEZOLID : 100 MG / 5 ML |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 100 MG / 5 ML |
| Dosage form | POWDER FOR SUSPENSION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01XX08 LINEZOLID |
| AHFS class | 08:12.28.24 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 04-Aug-2010 |
| Original market date | 2010-08-04 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02243686 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2243686 |
| Brand name | ZYVOXAM |
| Active ingredient / INN | LINEZOLID : 100 MG / 5 ML |
| ATC code | J01XX08 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01 |
| AHFS class | 08:12.28.24 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | PFIZER CANADA ULC |
How is it stored and handled?
Store reconstituted suspension at room temperature (15 - 30 ° C). Use within 21 days after reconstitution.
How is it supplied?
- 300 mL bag (600 mg linezolid)
Which pack is which?
| Strength on the label | 100 MG / 5 ML |
|---|---|
| Dosage form | POWDER FOR SUSPENSION |
| Route | ORAL |
| Packaging as described in the monograph | - 300 mL bag (600 mg linezolid) |
| Storage | Store reconstituted suspension at room temperature (15 - 30 ° C). Use within 21 days after reconstitution. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Is LINEZOLID in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01XX08 LINEZOLID. 8 of 19 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-LINEZOLID | 600 MG | TABLET | APOTEX INC | MARKETED | DIN 02426552 |
| JAMP LINEZOLID | 600 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02520354 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02539748 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02430827 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02481278 |
| SANDOZ LINEZOLID | 600 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02422689 |
| ZYVOXAM | 2 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02243685 |
| LINEZOLID | 600 MG | TABLET | PANDA PHARMACEUTICALS INC. | CANCELLED PRE MARKET | DIN 02457903 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | DIN 02429527 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | DIN 02402637 |
Who else supplies LINEZOLID worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LINEZOLID appears in 784 registered pack listings across 12 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does LINEZOLID cost around the world?
LINEZOLID is listed on 15 national price registers Nexara tracks, across 158 pack listings published on 15 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| South Africa | single exit price | 23 | 25 | 01 Sep 2026 |
| Saudi Arabia | public | 14 | 16 | 01 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 7 | 15 | 03 Sep 2026 |
| United States | acquisition | 2 | 15 | 03 Sep 2026 |
| Czechia | max producer price (ex-factory) | 6 | 12 | 03 Sep 2026 |
| Romania | max producer price | 9 | 12 | 03 Sep 2026 |
| Greece | producer price (ex-factory) | 11 | 11 | 03 Sep 2026 |
| Bahrain | retail (max) | 6 | 10 | 01 Sep 2026 |
| United Arab Emirates | public | 9 | 9 | 31 Aug 2026 |
| Norway | max AUP (pharmacy retail) | 4 | 8 | 07 Sep 2026 |
| Sweden | AIP (pharmacy purchase price) | 7 | 7 | 03 Sep 2026 |
| Italy | prezzo al pubblico (classe A) | 3 | 5 | 02 Sep 2026 |
| Italy | ex-factory (classe H) | 3 | 5 | 02 Sep 2026 |
| Slovakia | categorised final price | 4 | 4 | 02 Sep 2026 |
| United Kingdom | hospital | 2 | 2 | 31 Aug 2026 |
| Luxembourg | reimbursement | 2 | 2 | 05 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.